480 related articles for article (PubMed ID: 27993144)
1. Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept.
Verazza S; Davì S; Consolaro A; Bovis F; Insalaco A; Magni-Manzoni S; Nicolai R; Marafon DP; De Benedetti F; Gerloni V; Pontikaki I; Rovelli F; Cimaz R; Marino A; Zulian F; Martini G; Pastore S; Sandrin C; Corona F; Torcoletti M; Conti G; Fede C; Barone P; Cattalini M; Cortis E; Breda L; Olivieri AN; Civino A; Podda R; Rigante D; La Torre F; D'Angelo G; Jorini M; Gallizzi R; Maggio MC; Consolini R; De Fanti A; Muratore V; Alpigiani MG; Ruperto N; Martini A; Ravelli A;
Pediatr Rheumatol Online J; 2016 Dec; 14(1):68. PubMed ID: 27993144
[TBL] [Abstract][Full Text] [Related]
2. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
[TBL] [Abstract][Full Text] [Related]
3. Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis.
Khraishi M; Millson B; Woolcott J; Jones H; Marshall L; Ruperto N
Pediatr Rheumatol Online J; 2019 Sep; 17(1):64. PubMed ID: 31500631
[TBL] [Abstract][Full Text] [Related]
4. Etanercept concentration and immunogenicity do not influence the response to Etanercept in patients with juvenile idiopathic arthritis.
Bader-Meunier B; Krzysiek R; Lemelle I; Pajot C; Carbasse A; Poignant S; Melki I; Quartier P; Choupeaux L; Henry E; Treluyer JM; Belot A; Hacein-Bey-Abina S; Urien S
Semin Arthritis Rheum; 2019 Jun; 48(6):1014-1018. PubMed ID: 30396593
[TBL] [Abstract][Full Text] [Related]
5. Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.
Constantin T; Foeldvari I; Vojinovic J; Horneff G; Burgos-Vargas R; Nikishina I; Akikusa JD; Avcin T; Chaitow J; Koskova E; Lauwerys BR; Calvo Penades I; Flato B; Gamir ML; Huppertz HI; Jaller Raad JJ; Jarosova K; Anton J; Macku M; Otero Escalante WJ; Rutkowska-Sak L; Trauzeddel R; Velez-Sanchez PJ; Wouters C; Wajdula J; Zang C; Bukowski J; Woodworth D; Vlahos B; Martini A; Ruperto N;
J Rheumatol; 2016 Apr; 43(4):816-24. PubMed ID: 26932344
[TBL] [Abstract][Full Text] [Related]
6. Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Davies R; Southwood TR; Kearsley-Fleet L; Lunt M; Hyrich KL;
Arthritis Rheumatol; 2015 Sep; 67(9):2487-94. PubMed ID: 25989609
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication.
Aquilani A; Marafon DP; Marasco E; Nicolai R; Messia V; Perfetti F; Magni-Manzoni S; De Benedetti F
J Rheumatol; 2018 Jul; 45(7):956-961. PubMed ID: 29717035
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
10. Cytokine Biomarkers of Disease Activity and Therapeutic Response after Initiating Methotrexate Therapy in Patients with Juvenile Idiopathic Arthritis.
Funk RS; Chan MA; Becker ML
Pharmacotherapy; 2017 Jun; 37(6):700-711. PubMed ID: 28475276
[TBL] [Abstract][Full Text] [Related]
11. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
[TBL] [Abstract][Full Text] [Related]
12. Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry.
Horneff G; Schulz AC; Klotsche J; Hospach A; Minden K; Foeldvari I; Trauzeddel R; Ganser G; Weller-Heinemann F; Haas JP
Arthritis Res Ther; 2017 Nov; 19(1):256. PubMed ID: 29166924
[TBL] [Abstract][Full Text] [Related]
13. Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients.
Southwood TR; Foster HE; Davidson JE; Hyrich KL; Cotter CB; Wedderburn LR; Hull RG; Venning HE; Rahman JK; Cummins CL;
Rheumatology (Oxford); 2011 Jan; 50(1):189-95. PubMed ID: 21047801
[TBL] [Abstract][Full Text] [Related]
14. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
15. Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes.
Su Y; Yang YH; Chiang BL
Clin Rheumatol; 2017 Sep; 36(9):1997-2004. PubMed ID: 28540607
[TBL] [Abstract][Full Text] [Related]
16. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Beukelman T; Lougee A; Matsouaka RA; Collier D; Rumsey DG; Schenfeld J; Stryker S; Twilt M; Kimura Y;
Pediatr Rheumatol Online J; 2021 Aug; 19(1):131. PubMed ID: 34419107
[TBL] [Abstract][Full Text] [Related]
17. Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study.
Levälampi T; Kärki J; Rebane K; Vähäsalo P; Malin M; Kröger L; Grönlund MM; Backström M; Pohjankoski H; Kautiainen H; Jokiranta S; Aalto K
Pediatr Rheumatol Online J; 2023 Mar; 21(1):27. PubMed ID: 36949461
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
Horneff G; Burgos-Vargas R; Constantin T; Foeldvari I; Vojinovic J; Chasnyk VG; Dehoorne J; Panaviene V; Susic G; Stanevica V; Kobusinska K; Zuber Z; Mouy R; Rumba-Rozenfelde I; Breda L; Dolezalova P; Job-Deslandre C; Wulffraat N; Alvarez D; Zang C; Wajdula J; Woodworth D; Vlahos B; Martini A; Ruperto N;
Ann Rheum Dis; 2014 Jun; 73(6):1114-22. PubMed ID: 23696632
[TBL] [Abstract][Full Text] [Related]
19. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors.
Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic DS; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Johnson A; Huang B; Lovell DJ;
J Rheumatol; 2014 Jun; 41(6):1163-70. PubMed ID: 24786928
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
